A Phase 1 interventional study of Metformin and PF-04965842 in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-05.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.
Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 19th largest by enrollment, is one of 2 that started in 2019, is one of 3 in phase 1, and was the 8th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
Pfizer · Sites in United States, China, Hungary and 4 more countries
Ages 2–11
Pfizer
Ages 2–5
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 150 across the 20 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 5 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
58 studies in Dermatitis, Atopic by Pfizer: 11 open now, 13 under way, 4 of them phase 3. Of 43 finished, 34 (79%) have results posted.
Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 46th largest by enrollment of the 47 interventional ones that give a count, is one of 8 that started in 2019, is one of 13 in phase 1, and was the 20th registered.
Pfizer’s Dermatitis, Atopic studies by the year they started, since 2009.
1 of the studies testing abrocitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07848074Fondazione Policlinico Universitario Agostino Gemelli IRCCSAbrocitinib Dose Tapering in Patients With Atopic Dermatitis | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing abrocitinib in Dermatitis, Atopic, from their registry updates:
Among Pfizer’s 58 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, randomized, 2 way crossover, open label study of the effect of PF-04965842 on metformin (a probe for MATE1/2K activity) PK in healthy adult participants. The effect of PF-04965842 on N1-methylnicotinamide (NMN; an endogenous biomarker for MATE1/2K) PK and its correlation to the effect on metformin PK will also be assessed. Participants will be randomized to 1 of 2 treatment sequences as described below. A total of 12 healthy male and/or female participants will be enrolled in the study so that 6 participants will be enrolled in each treatment sequence. Each treatment sequence will consist of 2 periods.
This is a Phase 1, randomized, 2 way crossover, open label study of the effect of PF-04965842 on metformin (a probe for MATE1/2K activity) PK in healthy adult participants. The effect of PF-04965842 on N1-methylnicotinamide (NMN; an endogenous biomarker for MATE1/2K) PK and its correlation to the effect on metformin PK will also be assessed. Participants will be randomized to 1 of 2 treatment sequences as described below. A total of 12 healthy male and/or female participants will be enrolled in the study so that 6 participants will be enrolled in each treatment sequence. Each treatment sequence will consist of 2 periods. Participants who discontinue from the study may be replaced at the sponsor's discretion. The replacement participant will receive the same treatment sequence as the participant who discontinued.
Participants will be screened within 28 days of the first dose of investigational product. Participants will report to the clinical research unit (CRU) the day prior to Day 1 (ie Day -1) dosing in Period 1 for both treatment sequences. In both sequences, participants will remain in the CRU for a total of 8 days and 7 nights (including Period 1 and Period 2). There will be a minimum 4 day washout period between metformin dosing events. NMN and metformin PK will be assessed in plasma and urine over 24 and 48 hours, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in sequence 1 will received treatment A (metformin) in Period 1 then complete at least 4 days of washout and continue to period 2 where treatment B (PF-04965842 + metformin) will be administered.
Drug: Metformin · Drug: PF-04965842
Patients in Sequence 2 will start treatment B (PF-04965842 + metformin) then go through a washout period of at least 4 days and continue to Period 2 where treatment A (metformin) will be administered.
Drug: Metformin · Drug: PF-04965842
Commercially available metformin (GLUCOPHAGE®) as 500 mg tablets.
Also known as: Glucophage
PF 04965842 100 mg tablets
Renal Clearance (CLr) of Metformin
CLr was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).
Time frame: For both Period 1 and Period 2 at intervals of 0-12, 12-24, 24-36, and 36-48 hours post metformin dose
Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Metformin
AUCinf is a measure of the serum concentration of the drug over time. It was used to characterize drug absorption.
Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Maximum Plasma Concentration (Cmax) of Metformin
Cmax is maximum observed plasma concentration.
Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Time for Cmax (Tmax) of Metformin
Tmax of metformin administrated with or without PF-04965842.
Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Area Under the Plasma Concentration Time Profile From Time 0 to the Time of Last Quantifiable Concentration (AUClast) of Metformin
AUClast of metformin administrated with or without PF-04965842.
Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Apparent Clearance (CL/F) of Metformin
CL/F is a quantitative measure of the rate at which drug was removed from the blood.
Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Apparent Volume of Distribution (Vz/F) of Metformin
Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Terminal Half-life (t1/2) of Metformin
t1/2 is the time measured for the plasma concentration to decrease by one half.
Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Cumulative Amount of Drug Recovered Unchanged in Urine From 0 to 48 Hours (Ae) of Metformin
Ae is the cumulative amount of drug recovered unchanged in urine during the dosing interval. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Sample volume = (urine weight in gram \[g\]/1.020), where 1.020 g/mL is the approximate specific gravity of urine.
Time frame: For both Period 1 and Period 2 at intervals of 0-12, 12-24, 24-36, and 36-48 hours post metformin dose
Percent of Dose Recovered Unchanged in Urine From 0 to 24 Hours (Ae%) of Metformin
Ae% is percent of dose recovered unchanged in urine from 0 to 24 hours post-dose of metformin.
Time frame: For both Period 1 and Period 2 at intervals of 0-12 and 12-24 hours post metformin dose
Number of Participants With Laboratory Abnormalities
Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocytes, ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, prothrombin intl. normalized ratio, large unstained cells/leukocytes and large unstained cells), clinical chemistry (bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, urea, creatinine, urate, sodium, potassium, chloride, calcium, bicarbonate, urobilinogen and glucose -FASTING), urinalysis (specific gravity, pH, urine glucose, ketones, urine protein, urine hemoglobin, urine bilirubin, nitrite and leukocytes). Clinical significance of laboratory parameters is determined at the investigator's discretion.
Time frame: Screening (within 28 days prior to Day 1) to Day 7
Number of Participants With Categorical Vital Signs Meeting Pre-defined Criteria
Criteria for change in vital signs: pulse rate value less than (\<) 40 beats per minute (bpm) or value over than (\>) 120 bpm, systolic blood pressure (SBP) value \< 90 millimeter of mercury (mmHg) or change from baseline (Chg) equal to or over than (≥) 30 mmHg increase or ≥ Chg 30 mmHg decrease, diastolic blood pressure (DBP) value \< 50 mmHg or Chg ≥ 20 mmHg increase or Chg ≥ 20 mmHg decrease.
Time frame: Screening (within 28 days prior to Day 1) to Day 7
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (All Causalities and Treatment-related)
AEs with all causalities were any untoward medical occurrences in a study subject administered a product or medical device which did not necessarily had causal relationship with the treatment or usage. An SAE was an AE resulting in any of the following endpoints or deemed significant for any other reason: death; life threatening (immediate risk of death); inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Day 1 up to Day 40 (35 days after the last dose of metformin)
Percentage of Participants With Treatment-Emergent AEs and SAEs (All Causalities and Treatment-related)
AEs with all causalities were any untoward medical occurrences in a study subject administered a product or medical device which did not necessarily had causal relationship with the treatment or usage. An SAE was an AE resulting in any of the following endpoints or deemed significant for any other reason: death; life threatening (immediate risk of death); inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Day 1 up to Day 40 (35 days after the last dose of metformin)
| Milestone | Metformin Then Metformin + PF-04965842 | Metformin + PF-04965842 Then Metformin |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | Metformin Then Metformin + PF-04965842 | Metformin + PF-04965842 Then Metformin |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | Metformin Then Metformin + PF-04965842 | Metformin + PF-04965842 Then Metformin |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
CLr was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).
| litre per hour (L/hr) | Metformin + PF-04965842 | Metformin |
|---|---|---|
| Renal Clearance (CLr) of Metformin | 32.18 ± 39 | 33.33 ± 28 |
AUCinf is a measure of the serum concentration of the drug over time. It was used to characterize drug absorption.
| nanogram*hour per milliliter (ng*hr/mL) | Metformin + PF-04965842 | Metformin |
|---|---|---|
| Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Metformin | 5050 ± 16 | 5202 ± 19 |
Cmax is maximum observed plasma concentration.
| nanogram per milliliter (ng/mL) | Metformin + PF-04965842 | Metformin |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Metformin | 634.7 ± 14 | 720.7 ± 20 |
Tmax of metformin administrated with or without PF-04965842.
| Hours (hrs) | Metformin + PF-04965842 | Metformin |
|---|---|---|
| Time for Cmax (Tmax) of Metformin | 4.00 (2.00 to 4.00) | 4.00 (1.00 to 4.00) |
AUClast of metformin administrated with or without PF-04965842.
| ng*h/mL | Metformin + PF-04965842 | Metformin |
|---|---|---|
| Area Under the Plasma Concentration Time Profile From Time 0 to the Time of Last Quantifiable Concentration (AUClast) of Metformin | 4849 ± 18 | 5145 ± 18 |
CL/F is a quantitative measure of the rate at which drug was removed from the blood.
| L/hr | Metformin + PF-04965842 | Metformin |
|---|---|---|
| Apparent Clearance (CL/F) of Metformin | 98.97 ± 16 | 96.13 ± 19 |
Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
| liter (L) | Metformin + PF-04965842 | Metformin |
|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Metformin | 1087 ± 42 | 1211 ± 37 |
t1/2 is the time measured for the plasma concentration to decrease by one half.
| hrs | Metformin + PF-04965842 | Metformin |
|---|---|---|
| Terminal Half-life (t1/2) of Metformin | 8.318 ± 4.2508 | 9.261 ± 3.5165 |
Ae is the cumulative amount of drug recovered unchanged in urine during the dosing interval. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Sample volume = (urine weight in gram \[g\]/1.020), where 1.020 g/mL is the approximate specific gravity of urine.
| milligram (mg) | Metformin + PF-04965842 | Metformin |
|---|---|---|
| Cumulative Amount of Drug Recovered Unchanged in Urine From 0 to 48 Hours (Ae) of Metformin | 168.0 (70.7 to 210) | 170.5 (114 to 248) |
Ae% is percent of dose recovered unchanged in urine from 0 to 24 hours post-dose of metformin.
| percentage of dose | Metformin + PF-04965842 | Metformin |
|---|---|---|
| Percent of Dose Recovered Unchanged in Urine From 0 to 24 Hours (Ae%) of Metformin | 33.60 (14.1 to 42.0) | 34.05 (22.7 to 49.7) |
Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocytes, ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, prothrombin intl. normalized ratio, large unstained cells/leukocytes and large unstained cells), clinical chemistry (bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, urea, creatinine, urate, sodium, potassium, chloride, calcium, bicarbonate, urobilinogen and glucose -FASTING), urinalysis (specific gravity, pH, urine glucose, ketones, urine protein, urine hemoglobin, urine bilirubin, nitrite and leukocytes). Clinical significance of laboratory parameters is determined at the investigator's discretion.
| Participants | Metformin + PF-04965842 | Metformin |
|---|---|---|
| Number of Participants With Laboratory Abnormalities | 0 | 0 |
Criteria for change in vital signs: pulse rate value less than (\<) 40 beats per minute (bpm) or value over than (\>) 120 bpm, systolic blood pressure (SBP) value \< 90 millimeter of mercury (mmHg) or change from baseline (Chg) equal to or over than (≥) 30 mmHg increase or ≥ Chg 30 mmHg decrease, diastolic blood pressure (DBP) value \< 50 mmHg or Chg ≥ 20 mmHg increase or Chg ≥ 20 mmHg decrease.
| Participants | Metformin + PF-04965842 | Metformin |
|---|---|---|
| Supine DBP Value < 50 mmHg | 0 | 0 |
| Supine DBP Chg ≥ 20 mmHg increase | 0 | 0 |
| Supine DBP Chg ≥ 20 mmHg decrease | 0 | 0 |
| Supine pulse rate Value < 40 bpm | 0 | 0 |
| Supine pulse rate Value > 120 bpm | 0 | 0 |
| Supine SBP Value < 90 mmHg | 0 | 0 |
| Supine SBP Chg ≥ 30 mmHg increase | 0 | 0 |
| Supine SBP Chg ≥ 30 mmHg decrease | 0 | 0 |
AEs with all causalities were any untoward medical occurrences in a study subject administered a product or medical device which did not necessarily had causal relationship with the treatment or usage. An SAE was an AE resulting in any of the following endpoints or deemed significant for any other reason: death; life threatening (immediate risk of death); inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| Participants | Metformin + PF-04965842 | Metformin |
|---|---|---|
| AEs (all causalities) | 6 | 4 |
| AEs (treatment-related) | 5 | 4 |
| SAEs (all causalities) | 0 | 0 |
| SAEs (treatment-related) | 0 | 0 |
AEs with all causalities were any untoward medical occurrences in a study subject administered a product or medical device which did not necessarily had causal relationship with the treatment or usage. An SAE was an AE resulting in any of the following endpoints or deemed significant for any other reason: death; life threatening (immediate risk of death); inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| percentage of participants | Metformin + PF-04965842 | Metformin |
|---|---|---|
| AEs (all causalities) | 50.0 | 33.3 |
| AEs (treatment-related) | 41.7 | 33.3 |
| SAEs (all causalities) | 0.0 | 0.0 |
| SAEs (treatment-related) | 0.0 | 0.0 |
Collected over Day 1 up to Day 40 (35 days after the last dose of metformin). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metformin + PF-04965842 | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Metformin | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Event | Metformin + PF-04965842 | Metformin |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/12 | 3/12 |
| Abdominal discomfortGastrointestinal disorders | 1/12 | 0/12 |
| Anorectal discomfortGastrointestinal disorders | 1/12 | 0/12 |
| NauseaGastrointestinal disorders | 1/12 | 0/12 |
| FatigueGeneral disorders | 0/12 | 1/12 |
| NasopharyngitisInfections and infestations | 0/12 | 1/12 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/12 | 1/12 |
| Neck painMusculoskeletal and connective tissue disorders | 1/12 | 0/12 |
All 12 participants who were randomized to study treatment.
| Age, Continuous(Years) | All Participants |
|---|---|
| Mean | 39.0 ± 8.42 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 0 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 11 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 1 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jan 2019 to primary completion in Feb 2019, 1 month.
Results were first posted in Feb 2020, 11 months after primary completion.
Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 1 month is below that.
Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrocitinib